SLC12A5 and Huntington disease: Noteworthily, recent works have now potentially indicated that pharmacological enhancement of KCC2 function could reactivate dormant relay circuits in injured mouse and patient brain, leading to functional recovery and the amelioration of neuronal abnormality and disease phenotype associated with mouse and human models of neurological disorders including HD [58,59,60,86,88,89].